Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yudan Shengui Capsule
- Development stage
- Unknown
- Lead developer
- Shanghai Yudan Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Yudan Shengui Capsule is a Traditional Chinese Medicine (TCM) oral formulation developed by Shanghai Yudan Pharmaceutical. It is primarily indicated for the treatment of cardiovascular and renal conditions, including coronary heart disease angina, acute myocardial infarction, and early diabetic nephropathy. The therapeutic mechanism is described in TCM terms as tonifying qi and warming yang, while simultaneously activating blood circulation and resolving blood stasis. The product is approved in China (Approval No. 国药准字 Z20000060) and is typically administered as a 0.3g oral capsule.
- Brand names
- Yudan Shengui Capsule玉丹参桂胶囊
- Other names
- Yudan Shengui Jiaonang
02
Targets
IL1B (Interleukin-1 beta)NF-κBTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Yudan Shengui Capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yudan Shengui Capsule.